scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference BURLINGTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00AM ET. Mr. Tucker will also ...
scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and positive topline pivotal PK data for our Autoinjector Company to host investor conference call and webcast today, Wednesday, August 14th, at 4:30pm ET BURLINGTON, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- scP...
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants to purchase up ...
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million The term loan refinances existing debt principal; lowers coupon, extends interest-only period for four additional years, and lowers minimum cash requirement to $5 million BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commerciali...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class Indication expansion allows for the use of FUROSCIX in NYHA Class IV chronic heart failure patients BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializi...
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental New Drug Application (sNDA) submission to the FDA by year-end 2024 BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmac...
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (“Shares”) of its common stock or, in lieu of Shares, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Sha...
scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024 Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, August 14, 2024,...
scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025 BURLINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the U.S. Food an...
Remain Overweight Large-Cap Growth Mega-cap growth names such as AMZN, TSLA, MSFT, GOOGL, and META have picked up the slack as semiconductors (SMH, SOXX, NVDA, AVGO, etc.) are simply consolidating after getting extended. This was a possibility we discussed in last week's Compass (6/25/24), which means we are not seeing any lasting rotation away from large-cap growth. We remain bullish on all of the names listed (including the semiconductors), and we continue to recommend an overweight to large-...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.